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Primary immunodeficiency disease (PID) comprises a genetically 
heterogeneous group of disorders caused by defects in components of 
the immune system. PIDs affect different components of the innate 
and adaptive immune systems, including neutrophils, macrophages, 
dendritic cells, complement proteins, natural killer (NK) cells, and 
T- and B-lymphocytes.[1 2]
Classification
Most PIDs are caused by mutations in single genes but the variable 
penetrance of these mutations results in diverse phenotypes and 
severity, which makes recognition and differential diagnosis 
difficult.[3,4] Owing to this complexity, the International Union of 
Immunological Societies (IUIS) Expert Committee on Primary 
Immunodeficiency has developed a classification for PID with the 
goal of facilitating diagnosis and treatment. According to the last 
updated report in 2015, PIDs are categorised into nine major groups 
(Table 1).[5]
Clinical manifestations
Individuals suffering from PIDs are more prone to recurrent and 
chronic infections with a number of different infectious agents, which 
cause significant morbidity and mortality. Although impairment of 
immune function can affect various organs, the most common sites 
of infection are the sinopulmonary system and the gastrointestinal 
tract. While unusual organisms generally cause these infections, 
typical infections that are atypical in length and severity are more 
often observed and may lead to lethal outcomes. In addition to 
susceptibility to infections, a poorly regulated immune system in PID 
patients may lead to inflammation, autoimmunity and malignancy.[2]
Global prevalence of PID
While PIDs are individually quite rare, collectively they represent a 
significant burden of disease. Recent studies which have extrapolated 
the prevalence of PID from registry data have shown that the disease 
may be more common than previously estimated[6-10] and, in fact, it 
has been suggested that the prevalence and incidence of PIDs may be 
as high as those observed for diseases such as leukaemia.[6] 
To estimate the global prevalence of PID in 2013, Bousfiha et 
al.[6] used data from continental and national registries in specific 
records from the Australia/New Zealand registry[7] and two specific 
epidemiological surveys conducted in the USA.[8,9] The prevalence of 
PIDs in different countries was extrapolated from these registries and 
surveys based on the populations of each country. It is estimated that 
as many as 6 million people may be living with a PID worldwide,[6] 
whereas only 27 000 - 60 000 (0.45 - 1%) have been registered in 
national registries and the Jeffrey Modell Centers Network (JMCN). 
Table 2 illustrates the frequency of PID worldwide as estimated in the 
Bousfiha et al.[6] study.
In an attempt to report all PID cases diagnosed worldwide 
since 2013, the Jeffrey Modell Foundation (JMF) has launched an 
annual survey in 358 institutions within the JMCN, covering 86 
countries on 6 continents. In its latest report in 2018, JMF indicated 
that 187 988 PID patients were being followed globally. A total of 
94 024 were identified as having a specific named PID.[10] According 
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to this report, the subgroup ‘predominantly antibody deficiencies’ 
comprising 45% of the PID patients identified is the leading global PID 
followed by ‘combined immunodeficiency with associated or syndromic 
features’ in 13% of patients. This study also showed that some PIDs are 
more common in certain geographic areas than others.[10]
As seen above, different studies have generated inconsistent 
results. Moreover, worldwide data registries are not able to provide 
full coverage of PID patients at the present time. Therefore, the 
identification of PID patients is confronted by an underreporting 
bias. Regardless of these challenges, PIDs are clearly more common 
than generally thought.
Diagnosis
There is a lack of awareness of PIDs among the public and healthcare 
workers, resulting in delays in diagnosis. On the other hand, an 
important issue affecting patient outcomes is the time interval 
between the onset of symptoms and making a diagnosis. Therefore, 
early diagnosis is critical to prevent significant morbidity and 
mortality. In order to raise the index of suspicion among healthcare 
professionals and patients, the medical advisory board of the JMF 
identified 10 warning signs of PID (http://www.info4pi.org/aboutPI/
pdf/General10WarningSignsFINAL.pdf) (Table 3). Knowing these 
warning signs helps physicians to identify patients suitable for 
appropriate immunological evaluation.[2,14] The IUIS PID expert 
committee has also recently developed a phenotypic classification, 
which through nine algorithms helps clinicians with bedside 
diagnosis of PIDs.[15] Once an immunodeficiency is suspected, a 
thorough history and physical examination will further direct the 
initial workup for screening of the immune system. If the result of 
the initial evaluation is positive, further testing will be done. The 
definite diagnosis of a PID which is important for the management 
of patients and further genetic counseling is reached by molecular 
diagnosis.[16] However, despite scientific progress in the field, there 
are still inadequate laboratory resources and diagnostic methods in 
many countries.[17] In fact, variations observed in the number of cases 
reported from country to country could often be related to the lack of 
access to appropriate laboratory testing.[18]
Treatment
Most PIDs are chronic diseases and, once recognised, patients require 
specific care for the rest of their lives. However, the treatment of PID 
is complex and generally requires both supportive and definitive 
Table 1. Classification of PID from the IUIS Expert Committee for Primary Immunodeficiency[5]
1 Immunodeficiencies affecting cellular and humoral immunity (e.g. SCID)
2 Combined immunodeficiency with Associated or Syndromic Features (e.g. WAS, ataxia-telangiectasia)
3 Predominantly antibody deficiencies (e.g. agammaglobunaemia)
4 Diseases of immune dysregulation (e.g. Chediak-Higashi syndrome)
5 Congenital defects of phagocyte number function or both (e.g. LAD1)
6 Defects in intrinsic and innate immunity (e.g. MSMD)
7 Autoinflammatory disorders (e.g. familial Mediterranean fever)
8 Complement deficiencies (e.g. complement cascade component deficiencies)
9 Phenocopies of PID (e.g. autoimmune lymphoproliferative syndrome)
PID = primary immunodeficiency; SCID = severe combined immunodeficiency; WAS = Wiskott-Aldrich syndrome; LAD1 = leukocyte adhesion deficiency type 1; MSMD = Mendelian 
susceptibility to mycobacterial disease.
Table 2. Worldwide frequency of PID estimated by Boushifa et al.[6]
Region
Estimate of the
number of PID
patients based on a prevalence of 
5.6/100 000 inhabitants from the 
Australian Registry[7]
Estimate of the
number of PID
patients based on a prevalence of 
86.3/100 000 inhabitants from the 
Boyle and Buckley’s survey[8]
Estimate of the annual incidence 
of PID based on an incidence of
10.3/100 000 person years from 
Joshi et al.[9] Registry
Europe 41 401 638 015 76 148 18 392*
Africa 58 572 902 631 107 730 1 306†
North America 19 464 299 947 35 799 2 804‡
South America 22 214 342 336 40 858 3 321
Asia 235 617 3 631 027 433 367 3 841§
Oceania 2 082 32 082 3 829 1 209¶
Worldwide 390 546 6 018 593 718 326 60 364||
PID = primary immunodeficiency.
*Europe.
†North Africa.
‡USA.
§Japan and Iran.
¶Australia and New Zealand.
||2011 JMF registries.
Table 3. Ten warning signs of a PID in children
1 >4 ear infections in one year
2 >2 severe sinus infections in one year
3 >2 months of antibiotic treatment with little effect
4 >2 pneumonias per year
5 Insufficient weight gain or growth delay
6 Recurrent deep skin or organ abscesses (e.g. liver, lungs)
7 Persistent thrush in mouth or fungal infection on skin
8 Need for intravenous antibiotics to clear infections
9 >2 deep seated infections (e.g. septicaemia, meningitis)
10 Family history of a PID
PID = primary immunodeficiency.
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approaches carried out by a multidisciplinary team. Initial therapy 
for most patients is supportive and involves aggressive management 
of the infection, immunoglobulin (Ig) replacement therapy, and 
antibiotic and antifungal prophylaxis. Ig replacement therapy has 
proven to increase the survival rates and decrease the frequency 
of life-threatening infections, especially pneumonia in antibody-
deficient patients.[20-22] According to the 2018 JMF survey, 23 967 
patients were receiving Ig therapy worldwide.[10] While cytokine- and 
enzyme-replacement therapy are other treatment modalities for 
some of these patients, haematopoietic stem cell transplantation 
(HSCT) and gene therapy could be considered as the definitive 
cure for a group of more severe PIDs, such as severe combined 
immunodeficiency (SCID). [19,23,24]
An allogeneic HSCT involves the intravenous infusion of allogeneic 
haematopoietic stem cells into the recipient’s body usually after 
preparation of the recipient with a conditioning regimen, which 
permits some degree of donor cell engraftment and replacement 
of lymphohaematopoietic function.[26] This procedure was first 
performed in 1968 on a 22-month-old male infant suffering from 
SCID.[25] In the past 45 years, there have been great advances in the 
field of HSCT.[26] The remarkable improvements in allogeneic HSCT, 
despite the limitations of HSCT, e.g. the lack of human leukocyte 
antigen (HLA)-compatible donors and also complications such as 
graft-versus-host disease (GVHD), have increased interest in gene 
therapy for treating PID patients.[19] 
Gene therapy was first introduced in the early 1990s.[28,29] In this 
approach, a normal copy of the mutated and disease-related gene 
of the PID patient is introduced into the patient’s stem cells ex 
vivo using a viral vector, following which the transduced cells are 
transplanted back into the patient’s body.[19] Given the fact that 
disease-related genes have now been found for most PIDs, gene 
therapy may become an important treatment option for many of 
these conditions. However, gene therapy runs the risk of insertional 
mutagenesis which is dependent on the nature of the technology 
used, such as gene editing and the type of vector.[31] In 2018, the JMF 
reported on the total number of patients worldwide who had received 
HSCT or gene therapy: 4 421 and 181 patients, respectively.[10]
Methodology
In this review, we evaluated all studies published from the African 
continent in the field of PID regarding prevalence, epidemiology, 
case reports and genetic findings. To this end, we performed 
a literature search in PubMed using the keywords ‘prevalence’, 
‘incidence’, ‘primary immunodeficiency’, ‘genetic mutations’ and 
‘Africa’. We excluded studies on immunodeficiency due to human 
immunodeficiency virus (HIV) by using the keyword ‘not HIV’. In 
our search we had no filter regarding the year of publication of the 
articles. We identified many African studies on different aspects of 
PID from the northern and southern regions of the continent. We 
found only one study from western Africa but no studies from eastern 
or central Africa. However, it should be cautioned that findings from 
northern and southern Africa cannot necessarily be extrapolated to 
other regions on the African continent.
Results
When compared with other continents, Africa has experienced a 
delay with regard to PID diagnosis and care. However, with the 
establishment of the African Society for Immunodeficiencies (ASID; 
www.asid.ma) in Casablanca (Morocco) in 2008, there has been an 
increase in awareness on the continent of PIDs among physicians and 
the general public. Moreover, ASID has begun to collect data from 
PID patients for the purpose of creating an international registry. 
In recent years, different regions of the African continent have also 
been involved in hosting international congresses and workshops 
on PID and collaborating with experts from various parts of the 
world.[32] In fact, the regions of North Africa and the Middle East 
have joined efforts by hosting ‘The Middle East and North Africa 
Immunodeficiency’ (MENAID) meetings; it is hoped that this will 
help to improve the quality of life of patients with PID. What both 
regions have in common is their high prevalence of consanguineous 
marriages (20 - 60%) which results in a higher incidence of 
autosomal recessive PIDs.[32,33] Another example of a medical society 
in Africa that is driving the dissemination of medical information 
and influencing public opinion is the ‘Primary Immunodeficiency 
Diseases South Africa’ working group, which is an active Working 
Group of the Allergy Society of South Africa (ALLSA) and hosts 
annual congresses and meetings (www.allergysa.org). 
Prevalence of PID on the African 
continent
Very few studies have been conducted in Africa which specifically 
describe the prevalence and epidemiological features of PIDs 
on the continent. Those that have been conducted are shown in 
Table 4.[35-40] In the latest JMF global survey, 1 836 patients with 
PIDs out of a global total of 94 024 were from Africa.[10] Africa is 
the second most populous continent, suggesting that it should have 
a larger number of PID cases, yet its registry contains the smallest 
proportion of cases. Bousfiha et al.[6] estimated the prevalence of 
PID to be 902 631 cases in Africa. The exact prevalence of PID on 
the African continent remains unknown. 
Barbouche et al. [33] investigated the prevalence of PID in 
northern Africa by collecting data from PID referral clinics in 
Morocco, Egypt and Tunisia and found that the most prevalent 
immunodeficiency reported from Egypt and Tunisia was combined 
immunodeficiency (41% v. 27%), while that from Morocco was 
combined immunodeficiency with associated or syndromic features 
(34%). The authors concluded that the hallmark of their North 
African PID cohort was the high rate of autosomal recessive PIDs 
compared with the European Registry which is aligned with the high 
frequency of parental consanguinity in the region.
Novel mutations in the African 
population 
Many studies in the northern region of Africa describe an autosomal 
recessive transmission mode for PIDs and some have reported 
novel autosomal recessive gene mutations.[41-60] Due to this fact, the 
northern region of Africa seems to be a distinctive epidemiological 
area for the study of genetic diseases, such as PIDs, which has 
drawn the attention of many researchers in the past decade. Table 5 
illustrates some of the studies describing molecular characterisation, 
novel genetic mutations and founder effects of PIDs undertaken 
mainly in Africa.
Autosomal recessive PIDs are particularly frequent in North 
African populations, and a strong founder effect for specific mutations 
in PIDs has been reported. For example, the major histocompatibility 
complex (MHC) class II combined immunodeficiency has been 
described mainly in patients living in or originating from North 
African countries (predominantly the Maghrebian countries, i.e. 
Morocco, Algeria and Tunisia). Therefore, it has been considered 
to be a ‘Maghrebian disease’. In fact, several studies have reported a 
founder effect for the RFXANK gene mutation 752delG26 in these 
patients.[46,48,49,55,59] In 2011, Ouederni et al.[55] dated the founder event 
responsible for this mutation in this population to ~2 250 years ago. A 
study by Ben-Mustapha et al. [44] in 2014 reported a common founder 
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Table 5. Genetic studies on PID in Africa and elsewhere
Study
Country 
where 
study was 
undertaken
Patient number and 
origin PID studied Genetic findings
Studies indigenous to Africa
Glanzmann et al.[71] (2018) SA 1 SA family MSMD De novo heterozygous
4 bp deletion in exon 6 of IFN-γR1 at 
nucleotide 818 (818del4)
Glanzmann et al.[72] (2017) SA 1 SA family Aicardi-Goutières
syndrome
Homozygous c.1681_1682delAG; p. 
Ser561Phefs*61 mutation in exon 15 of 
SAMHD1
Schlechter et al.[73] (2017) SA 1 SA family Recessive atypical combined 
immunodeficiency
Homozygous c.G1033A p.Val345Met 
nucleotide variant situated in exon 5 of 
MAP3K14
Kinnear et al.[74] (2017) SA 1 Somalian family  THE-S Homozygous mutation (c.4507C > T 
rs200067423) in TTC37
Glanzmann et al.[75] (2017) SA 1 SA family Immunodeficiency with 
autoimmunity
Compound heterozygous variant in 
LRBA (NM_006726) (c 3296 C>G and 
c.3407 C>T).
Owen[41] (2015) SA 7 SA families Complement deficiency Complement C5 gene mutation 
c.754G>A:p.A252T; common in the 
Western Cape
Jlajla[42] (2014) Tunisia 1 Tunisian family C1q deficiency Novel g.5580G4C mutation 
Sassi et al. [43] (2014) Tunisia 6 patients 
from 2 Tunisian 
families 
Hyper IgE syndrome Novel homozygous mutations in PGM3 
in 2 Tunisian families 
Ben-Mustapha[44] (2014) Tunisia 6 Tunisian patients MSMD Founder effect for the c.298_305del 
mutation in the IL12B gene 
Baba[45] (2014) Morocco 12 CGD Four different mutations of CYBB, a 
recurrent mutation of NCF1 and a new 
mutation of NCF2 in three patients
Ben-Mustapha et al. [46] (2013) Tunisia 34 (belonging to 28 
Tunisian families)
MHC class II expression 
deficiency
Founder effect for the c.338-25_338del26 
mutation in the RFXANK gene in 25 
patients
Landouré et al.[47] (2013) Mali 3 patients from 1 
Malian family
Ataxia-telangiectasia Novel c.7985T > A mutation in ATM 
gene
Djidjik et al. [48] (2012) Algeria 11 Algerian patients MHC class II expression 
deficiency
Founder effect for the 752delG26 
mutation in RFXANK gene in 9 patients 
Naamane et al. [49] (2010) Morocco 10 Moroccan patients MHC class II expression 
deficiency
Founder effect for the 752delG26 
mutation in the RFXANK gene in 10 
patients
El Kares et al.[50] (2006) Tunisia 15 Tunisian patients CGD Two novel and recurrent mutations in 
NCF2 and CYBA gene
Pienaar et al.[51] (2003) SA 2 SA patients Hyper IgM First report of X-linked hyper IgM 
(HIGM1) from SA
Elloumi-Zghal et al. [52] (2002) Tunisia 5 Tunisian patients MSMD IL-12Rb1 gene mutation in 2 patients 
and IL-12p40 gene mutation in
3 patients;
first description of familial cytokine 
deficiency
Eley BS et al. [53] (2001) SA 5 SA patients SCID 3 with IL-2RγC deficiency; 
1 with RAG1 deficiency 
1 with IL-7Rα deficiency
Pienaar et al.[54] (2000) SA 5 SA patients X-linked 
agammaglobulinaemia
Btk gene mutation
...continued
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mutation for Mendelian susceptibility to mycobacterial disease 
(MSMD) arising ~1 100 years ago.
There are additional scattered studies from the region describing 
PID, including patients’ susceptibilities to various infections and case 
reports.[61-68]
Diagnosis of PID on the African 
continent 
Although basic laboratory tests are available for the diagnosis of 
PID in some African countries, there are still limitations with 
regard to specialised immunological and genetic tools required 
for more accurate investigations. Particular laboratory tests, e.g. 
specific antibodies (IgG subclasses) lymphocyte subpopulations 
and proliferation studies, and functional phagocyte tests, are only 
available in a very limited number of referral centres. 
With respect to molecular studies, many centres on the continent 
are in the early phases of development, with limited capacity 
for genetic diagnosis of some PIDs. There has been a recent 
drive in African referral centres to expand molecular diagnostic 
services for PID, which includes polymerase chain reaction (PCR) 
analysis of T-cell receptor excision circles (TREC) and Kappa-
deleting recombination excision circles (KREC) as part of a newborn 
screening programme for severe PIDs. Still, most centres work in 
collaboration with specialised laboratories abroad for occasional 
definitive diagnosis of selected PID cases.
In 2016, a private diagnostic laboratory in South Africa developed 
a targeted next-generation sequencing (NGS) gene panel consisting 
of 99 of the most frequently associated PID genes.[70] The panel 
can be used as both a molecular confirmation and a screening tool 
for 18 PID phenotypes found within the nine International Union 
of Immunological Societies (IUIS) PID classifications (Table 1). 
Furthermore, whole exome and transcriptome sequencing are 
currently being investigated for those more challenging cases in 
which clinical presentation is indicative of a PID when immunological 
investigations and targeted sequencing have proved uninformative. 
Table 6 shows the laboratory tests available for the diagnosis of 
PID in SA; these have been grouped into a stepwise investigative 
approach. All the tests indicated are available in SA and the public 
(government) sector has permission to refer this work to Ampath 
through the National Health Laboratory Services when clinically 
indicated. Lack of diagnostic facilities can cause delays in diagnosis 
and may ultimately compromise the clinical outcome of these 
patients.[33,34,36] 
Treatment options for PID in Africa
With an average mortality rate of 20% in northern and southern 
Africa, there are still considerable challenges in the region regarding 
the management and overall clinical outcome of PID patients.[34-37] 
Generally, 40% of PID patients in these regions receive intravenous 
immunoglobulin (IVIG)[34,35,40] despite limitations in the availability 
of IVIG in some regions.[33]
HSCT using haploidentical donors has been introduced as a 
treatment option in severe cases of PID but only in very few centres 
on the continent and with long waiting lists.[34-36] However, due to the 
cost morbidity and mortality associated with HSCT, clinicians are 
very cautious about administering gene therapy, specifically if the 
patient is fairly well controlled. 
Gene therapy as an option in the 
African continent 
According to the JMF global survey, there has been a significant 
increase in the number of patients receiving gene therapy worldwide, 
with the greatest number residing in Western Europe.[10] Although 
in 2016 the first retroviral long terminal repeat (LTR)-based vector 
received license for ex vivo gene therapy in SCID, many challenges 
still need to be overcome before gene therapy can be offered as a 
standard therapy for all patients.[76] To our knowledge, no centre on 
the African continent has performed gene therapy on PID patients 
to date. As the field of PIDs continues to grow and the number of 
children and adults diagnosed with PID in the region increases, gene 
therapy could become an effective treatment option for patients on 
the African continent in the future. 
Table 5. (continued) Genetic studies on PID in Africa and elsewhere
Study
Country 
where 
study was 
undertaken
Patient number and 
origin PID studied Genetic findings
Studies from outside Africa
Ouederni et al.[55] (2011) France 35 North African 
patients
MHC class II expression 
deficiency
Founder effect for the 752delG26 
mutation in the RFXANK gene in 35 
patients
Boisson-Dupuis[56] (2011) France 50 patients from 
Morocco, Iran and 
Turkey
MSMD Homozygosity for loss-of-function 
IL12RB1 alleles in 2 patients, 1 from 
Morocco and the other from Iran
Lennon-Duménil et al.[57] 
(2001)
France 1 North African patient MHC class II expression 
deficiency
Uncoordinated expression of the HLA-D 
genes in a new RFXANK gene mutation
Altare et al. [58] (2001) France 2 siblings from North 
Africa
MSMD Heterogeneity of the clinical phenotype 
associated with IL-12RB1 deficiency
Wiszniewski et al.[59] (2000) France 20 North African 
patients
MHC class II expression 
deficiency
Founder effect for the 752delG26 
mutation in the RFXANK gene in 17 
patients
Jouanguy et al.[60] (1996) France 1 Tunisian patient MSMD First report of INFγ receptor deficiency
PID = primary immunodeficiency; SA = South Africa; INFγ = interferon gamma; SAMHD1 = SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1; MAP3K14 = 
mitogen-activated protein kinase kinase kinase 14; THE-S = thrichohepatoenteric syndrome; LRBA = LPS responsive beige-like anchor protein; MSMD = Mendelian susceptibility to mycobacterial 
infection; C1q = serum complement subcomponent C1q; IgE = immunoglobulin E; PGM3 = phosphoglucomutase 3; IL = interleukin; CGD = chronic granulomatous disease; CYBB = cytochrome 
B-245 beta chain; NCF =  neutrophil cytosolic factor 1; MHC = major histocompatibility complex; RFXANK = regulatory Factor X-associated ankyrin-containing protein; CYBA = cytochrome 
B-245 alpha chain; IgM = immunoglobulin M; RAG1 =  recombination activating 1; Btk = bruton tyrosine kinase; HLA = human leukocyte antigen.
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Table 6. A stepwise approach to the laboratory diagnosis of PID*
Test Association
First-line investigations Exclude HIV
Assessment for atopy As indicated on history
Full blood count
• Differential count for neutrophil and 
lymphocyte numbers
• Platelet count and morphology
Lymphopaenia is an important indicator of possible SCID
Small platelets seen in WAS
• Serum Ig: G, M, A and E IgE should be tested in patients who may be at risk of 
hyper IgE syndrome
• TRECs and KREC PCR Used for neonatal screening for SCID and XLA on blood 
monospots – useful to do prior to giving live vaccines at 
birth
• CF screening Suspected on history and clinical examination
Second-line investigations IgG subclasses
Specific antibody response
• Pneumococcus and Haemophilus influenzae 
(targeted to polysaccharide-specific antigens)
• Tetanus, diphtheria and H. influenzae (target 
protein antigens)
IgG subclass deficiency and other immunodeficiencies 
Indicated with recurrent bacterial infections even in 
the presence of normal immunoglobulins. Patients have 
to be off immunoglobulin replacement therapy for 6 
months. If these antibody levels are decreased, the patient 
should be revaccinated and antibody responses should 
be repeated 4 weeks after vaccine boosting to determine 
an appropriate increase in specific antibody responses. 
Note that an unconjugated pneumococcal vaccine, e.g. 
Pneumovax, should be given to determine an appropriate 
polysaccharide antigen response.
Lymphocyte subsets 
• B cell numbers (CD19)
Absent in XLA where all immunoglobulin isotypes are 
severely reduced
T cell numbers (CD3)
T helper (CD4) and T suppressor (CD8)
Reduced in T cell defects combined immunodeficiencies 
and occasionally CVID
NK cells (CD16 and CD56) Isolated NK-cell deficiencies may be associated with 
recurrent herpes virus infections
Neutrophil function
• Neutrophil oxidative burst CGD
Third-line investigations Lymphocyte proliferation studies
• Response to mitogens e.g. 
phytohaemagglutinin PMA PMA +ionomycin 
anti-CD3 anti-CD3+IL2 
• Response to recall antigens e.g. Candida, 
tetanus, varicella-zoster virus
T cell deficiencies including SCID, chronic mucocutaneous 
candidiasis
Neutrophil antibodies Alloimmune and autoimmune neutropaenia
T cell maturation panel: Naïve and memory T cells Diagnosis of SCID and combined T cell defects 
Recent thymic emigrants (T cells) Very low in SCID
Can be used to monitor bone marrow regeneration post 
transplant
Memory B cells Memory B cells categorise subsets of CVID patients and 
are decreased in X-linked HIGM
Alpha/beta/ gamma/delta T cell receptor type Abnormal in leaky SCID, hypomorphic SCID T cell defects 
with oligoclonality
Total haemolytic complement
• Classic 
• Alternative
Mannan binding lectin (MBL)
Complement deficiencies
Patient may suffer from recurrent URTIs and may have 
a higher risk for severe meningococcal or pneumococcal 
infections.
Fourth-line investigations • Genetic testing Various PID panels available or exome sequencing as 
clinically indicated
• Complement studies 
• Confirmatory test
To be discussed with clinical immunologist
PID = primary immunodeficiency; HIV = human immunodeficiency virus; SCID = severe combined immunodeficiency; WAS = Wiskott-Aldrich syndrome; Ig = immunoglobulin;  
TREC = T cell receptor excision circles; KREC = Kappa receptor excision circles; PCR = polymerase chain reaction; XLA = X-linked agammaglobulinaemia; CF = cystic fibrosis; CD3 = cluster of 
differentiation 3; CVID = common variable immune deficiency; NK = natural killer;  CGD = chronic granulomatous disease; PMA = phorbol myristate acetate; IL = interleukin; URTIs = upper 
respiratory tract infections; MBL = mannan-binding lectin.
*Adapted from Suchard et al.[77] 
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In addition to the outcomes and efficacy of this form of treatment, 
elevated costs are a major concern. However, many believe that a one-
time cure could still save money in the long-term by reducing the need 
for expensive care. In 2014, Buckland et al. [69] reported that the cost 
of an allogeneic bone marrow transplant for a patient with a primary 
immunodeficiency was ≥£250 000. In contrast, the manufacture of 
autologous gene modified CD34+ cells could be achieved at a cost of 
~£15 000 - £30 000. The additional follow-up costs after gene therapy 
treatment for PIDs are also likely to be significantly less given that 
the length of hospital stay and long-term prophylactic medication 
requirements and other post-therapy complications are considerably 
reduced, compared with conventional HSCT.
Limitations regarding PID on the 
African continent
PID is mostly underdiagnosed in Africa and, although considerable 
progress has been achieved in parts of the continent, many challenges 
remain regarding awareness, diagnosis, registration and care of these 
patients.
At present, only 2 of the 54 countries on the continent have 
national registries: the Moroccan Society for PID (MSPID, www.pid-
moroccansociety.org) and the South African National PID Registry 
(https://www.pinsa.org.za/). Without national registries, accurate 
prevalence and incidence data cannot be gathered. Participation in 
these networks will establish earlier diagnosis and improve treatment 
and clinical care, resulting in an improvement in the quality of life of 
these patients. There is also a need to improve public health policy 
in this field.[6,33]
The lack of specialised physicians in the field of clinical 
immunology in many areas of the African continent negatively 
affects the management of PID patients in the region. The training of 
expert clinical immunologists could assist in raising awareness of PID 
in the medical community. In addition, networks such as Primary 
Immunodeficiency Diseases Network of South Africa (PINSA) and 
ASID could play an important role in creating awareness of PIDs on 
the continent. 
The burden of HIV and other epidemic illnesses, particularly in 
the sub-Saharan region, is likely to be a major contributor to the 
under-diagnosis of PID.[28] It is assumed that the expanding HIV 
epidemic, especially in SA, over the past 30 years has compromised 
clinical recognition of PID.[34] 
In addition to efforts aimed at increasing the awareness of PID in 
the region, there is a need for improvement in diagnosis. Conducting 
molecular and genetic studies in the region could support the future 
development of genetic counseling, prenatal diagnosis and gene 
therapy.[33]
Africa faces a number of challenges, which include a paucity of 
diagnostic facilities, limited expertise, as well as limited financial 
resources. These challenges may be overcome by creating diagnostic 
referral centers for PID on the continent. These specialised centres 
could potentially offer basic as well as definitive molecular diagnostic 
services at a lower cost and faster turnaround time than when 
samples are sent to international laboratories. 
Conclusion
With the exception of South and northern Africa, there appears 
to be limited activity in the field of PID on the African continent, 
resulting in lack of awareness, underdiagnoses, mismanagement 
and suboptimal care. Additionally, as the field of PID is continually 
growing, advanced therapeutic modalities are rapidly expanding 
worldwide and options such as gene therapy are becoming a reality. 
Given the unique genetic mutations reported in PID patients on the 
African continent and the feasibility of HSCT and gene therapy, these 
new therapeutic options should be considered. 
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